What sector does Procter & Gamble Health L belong to?

Procter & Gamble Health L operates in the Healthcare sector, specifically the Pharmaceuticals industry, and is listed on the NSE.

What is the current share price of PGHL?

As of the latest available quote, PGHL traded at ₹5,411.50. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of PGHL?

Procter & Gamble Health L has a price-to-earnings (P/E) ratio of about 25.19. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of PGHL?

The market capitalisation of Procter & Gamble Health L is approximately ₹8,983 Cr.

Is Procter & Gamble Health L profitable?

For its latest reported financial year, Procter & Gamble Health L recorded a net profit margin of about 23.22%.

Does PGHL pay a dividend?

Procter & Gamble Health L does not currently show a dividend yield in our data.

What is the return on equity (ROE) of PGHL?

Procter & Gamble Health L has a return on equity (ROE) of about 61.90%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of PGHL?

Over the past 52 weeks, PGHL has traded between a low of ₹4,707.00 and a high of ₹6,975.00.

Procter & Gamble Health L

PGHL NSE Healthcare Pharmaceuticals

₹5,411.50

-0.26%

Delayed · cached 15 min

Fair value analysis

PGHL

Procter & Gamble Health L

₹5,425.50

Close used for this calculation

₹5,278.15Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

65/100

Profitability21/25

Returns12/25

Balance Sheet21/25

Efficiency11/25

Growth9/25

Strong

Quality radar

Consensus fair value

₹5,278.15

Near FV

▼ -2.7% against the close used

Model range ₹1,195.19 – ₹8,379.14

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹1,195.19Fair value₹5,278.15Bull₹8,379.14

FairClose

52-week traded range

52W low ₹4,778.6052W high ₹6,918.50

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading close to the consensus fair value

Procter & Gamble Health L closed at ₹5,425.50, 2.8% above the consensus fair value of ₹5,278.15 drawn from 8 valuation models.

Financial DNA score 65/100 — Strong. P/E of 27.0x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

₹3,872.22

-28.6%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

₹1,195.19

-78.0%

√(22.5 × EPS × BVPS)

EPS=196.94, BVPS=322.37 · outside Graham range (P/E 27, P/B 16.8) — asset-light, treat as a rough floor

P/E Fair Value

₹7,030.76

+29.6%

EPS × 35.7x (sector P/E)

EPS=196.94, Sector P/E=35.7x

Peter Lynch (PEG)

₹2,461.75

-54.6%

EPS × Growth% (PEG = 1 is fair)

EPS=196.94, g=12.5%

EV/EBITDA

₹4,735.01

-12.7%

(EBITDA × 16.3x − Net Debt) ÷ Shares

EBITDA=4.83B

Dividend Discount (DDM)

₹8,379.14

+54.4%

D1 ÷ (r − g) where D1 = D0×(1+g)

D0=155.17, r=10%, g=8%

Reverse DCF

₹5,425.50

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 11.5% | Historical: 12.5%

Margin of Safety

₹3,024.54

-44.3%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=4032.72, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer